AbbVie (ABBV) Issues Update on Sans RBV Therapy for GT1 HCV Phase III

January 31, 2014 7:41 AM

AbbVie (NYSE: ABBV) announced the completion of its phase III clinical program and released results of four additional studies designed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found